KR101853605B1 - Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제 - Google Patents

Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제 Download PDF

Info

Publication number
KR101853605B1
KR101853605B1 KR1020157029564A KR20157029564A KR101853605B1 KR 101853605 B1 KR101853605 B1 KR 101853605B1 KR 1020157029564 A KR1020157029564 A KR 1020157029564A KR 20157029564 A KR20157029564 A KR 20157029564A KR 101853605 B1 KR101853605 B1 KR 101853605B1
Authority
KR
South Korea
Prior art keywords
compound
weeks
patient
treatment
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157029564A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129035A (ko
Inventor
배리 엠. 번스타인
산디프 두타
웨이 류
토마스 제이. 포드사데키
앤드류 엘. 캠벨
라지브 엠. 메논
츠-웨이 린
톈리 왕
왈리드 엠. 오니
Original Assignee
애브비 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101853605(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 애브비 인코포레이티드 filed Critical 애브비 인코포레이티드
Publication of KR20150129035A publication Critical patent/KR20150129035A/ko
Application granted granted Critical
Publication of KR101853605B1 publication Critical patent/KR101853605B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157029564A 2013-03-14 2014-03-14 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제 Expired - Fee Related KR101853605B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
US61/783,437 2013-03-14
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187011379A Division KR20180045055A (ko) 2013-03-14 2014-03-14 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제

Publications (2)

Publication Number Publication Date
KR20150129035A KR20150129035A (ko) 2015-11-18
KR101853605B1 true KR101853605B1 (ko) 2018-05-03

Family

ID=50771575

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157029564A Expired - Fee Related KR101853605B1 (ko) 2013-03-14 2014-03-14 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제
KR1020187011379A Abandoned KR20180045055A (ko) 2013-03-14 2014-03-14 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187011379A Abandoned KR20180045055A (ko) 2013-03-14 2014-03-14 Hcv 환자 치료용 직접 작용 항바이러스제 및 리바비린의 병용제

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR101853605B1 (enExample)
CN (3) CN108187056A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA030482B1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG11201507361YA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TW202002979A (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108187056A (zh) 2013-03-14 2018-06-22 艾伯维公司 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
JP2016534082A (ja) * 2013-10-25 2016-11-04 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
WO2015095572A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CA2943054A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
WO2017120108A1 (en) 2016-01-08 2017-07-13 Entrust Datacard Corporation Card printing mechanism with card return path
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
MX394461B (es) * 2016-09-23 2025-03-24 Abbvie Inc Ajuste de la dosis.
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
TW202012001A (zh) * 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004196A1 (en) 2009-06-11 2012-01-05 Abbott Labaoratories Anti-Viral Compounds
US20120070416A1 (en) 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
US20130102526A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Methods for Treating HCV

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110165119A1 (en) * 2008-06-10 2011-07-07 Maria Gloria Beumont Telaprevir dosing regimen
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
AR077060A1 (es) * 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
CN108187056A (zh) 2013-03-14 2018-06-22 艾伯维公司 用于治疗hcv患者的直接作用的抗病毒剂和利巴韦林的组合

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120004196A1 (en) 2009-06-11 2012-01-05 Abbott Labaoratories Anti-Viral Compounds
US20120070416A1 (en) 2010-09-21 2012-03-22 Enanta Pharmaceuticals, Inc. Macrocyclic Proline Derived HCV Serine Protease Inhibitors
US20130102526A1 (en) 2011-10-21 2013-04-25 Abbvie Inc. Methods for Treating HCV

Also Published As

Publication number Publication date
JP2019167347A (ja) 2019-10-03
MX2015012536A (es) 2016-01-12
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
TW202002979A (zh) 2020-01-16
TW201505633A (zh) 2015-02-16
CN105007921B (zh) 2018-12-11
DK2968302T3 (en) 2017-12-18
AU2018202581B2 (en) 2019-12-05
AU2018202581A1 (en) 2018-05-10
PL2968302T3 (pl) 2018-04-30
AU2014239322A1 (en) 2015-08-27
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
BR112015020918A2 (pt) 2017-07-18
EP2968302A1 (en) 2016-01-20
CN105007921A (zh) 2015-10-28
JP2016513703A (ja) 2016-05-16
EP3915559A1 (en) 2021-12-01
SI2968302T1 (en) 2018-04-30
EP2968302B1 (en) 2017-09-06
IL240445B (en) 2019-07-31
EP2968302B9 (en) 2019-02-13
EP3318258A1 (en) 2018-05-09
CA2901818A1 (en) 2014-09-25
AU2020201656A1 (en) 2020-03-26
CY1121474T1 (el) 2020-05-29
RS56735B1 (sr) 2018-03-30
KR20180045055A (ko) 2018-05-03
SMT201800017T1 (it) 2018-03-08
EP3733180A1 (en) 2020-11-04
ES2654109T3 (es) 2018-02-12
CA2901818C (en) 2021-05-04
US20140274934A1 (en) 2014-09-18
LT2968302T (lt) 2017-12-27
WO2014152635A9 (en) 2014-12-11
EA030482B1 (ru) 2018-08-31
EA201591701A1 (ru) 2016-02-29
KR20150129035A (ko) 2015-11-18
HK1213191A1 (en) 2016-06-30
JP6563894B2 (ja) 2019-08-21
AU2014239322B2 (en) 2018-04-05
HK1255257A1 (en) 2019-08-09
JP2019214585A (ja) 2019-12-19
CN108187056A (zh) 2018-06-22
CN109908353A (zh) 2019-06-21
SG11201507361YA (en) 2015-10-29
HUE036069T2 (hu) 2018-06-28
ZA201705080B (en) 2019-02-27
WO2014152635A1 (en) 2014-09-25
SG10201709840UA (en) 2018-01-30
IL240445A0 (en) 2015-09-24
HRP20171898T1 (hr) 2018-04-06
NO3090119T3 (enExample) 2018-03-31
PL2968302T4 (pl) 2018-04-30
EP3318258B1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
JP6621902B2 (ja) Ｃ型肝炎を治療するための２種の抗ウイルス剤の併用
AU2018202581B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
JP2019214578A (ja) Ｈｃｖを処置するための方法
HK40037284A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
HK1223817B (en) Combination of two antivirals for treating hepatitis c

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210426

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210426